East Sussex Healthcare NHS Trust
Oncotype DX Breast Cancer Testing
This is a contract result notice, not an open opportunity. Details from the official award data.
This sits in the lower-middle of the Health & Social Care band — a mid-scale opportunity. Based on 32,734 valued Health & Social Care tenders in our corpus.
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer.
It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Make the case to bid
Reveal who to approach at East Sussex Healthcare NHS Trust, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- be83749f-55db-4eb4-b59b-40aa06ac75c4
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- CF-3414000D0O000000rwimUAA
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Health & Social Care
East Sussex Healthcare NHS Trust’s tender network